On August 23, 2021 Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported that it will release second quarter 2021 results on Wednesday, September 8, 2021, and host a conference call at 8:30 a.m. EDT to discuss financial results and recent corporate developments (Press release, Affimed, AUG 23, 2021, View Source [SID1234586830]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call will be available via phone and webcast. To access the call, please dial +1 (409) 220-9054 for U.S. callers, or +44 (0) 8000 323836 for international callers, and reference passcode 6156773 approximately 15 minutes prior to the call. To access the live audio webcast of the conference call please visit the "Investors" section of company’s website at View Source A replay of the call will be archived on the Affimed website for 30 days after the call.

On August 23, 2021 Horizon Therapeutics plc (Nasdaq: HZNP) reported that the Company will participate in the following conferences (Press release, Horizon Therapeutics, AUG 23, 2021, View Source [SID1234586849]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Handelsbanken Life Science Innovation Day 2021 (Virtual)

Date: Wednesday, Aug. 25, 2021
Presentation time: 10 a.m. ET
Morgan Stanley 19th Annual Global Healthcare Conference (Virtual)

Date: Friday, Sept. 10, 2021
Presentation time: 10:15 a.m. ET
The conference presentations will be webcast live and may be accessed by visiting Horizon’s website at View Source A replay of each webcast will be available following the events.

On August 23, 2021 Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, reported that it has been awarded a Top Workplaces honor by the Bay Area News Group for the eighth consecutive year (Press release, Veracyte, AUG 23, 2021, View Source [SID1234586815]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The annual award is based solely on employee feedback gathered through an anonymous, third-party survey administered by Energage, LLC, a leading provider of technology-based engagement tools. The survey measures 15 culture drivers that are critical to organizational success, including alignment, execution and engagement.

Veracyte employees participating in the 2021 Top Workplaces survey ranked the company most highly for doing things efficiently and well, having senior managers who understand what is happening at the company, holding meetings that make good use of employee time, having strong interdepartmental coordination, going in the right direction, and operating by strong values.

"The results of this survey suggest that Veracyte employees at all levels feel confident in the quality of our work, leadership and processes, and that they believe in our strategy," said Marc Stapley, Veracyte’s chief executive officer. "As we continue our global expansion, we are committed to ensuring that Veracyte remains a top workplace for every one of our employees worldwide. This has been a core Veracyte value since the company’s 2008 founding, and will be essential to achieving our vision of improving outcomes for patients all over the world at every step of their journey."

The Bay Area News Group published the complete list of 2021 Top Workplaces winners on Sunday, August 22. The list is available at the Bay Area News Group website.

On August 23, 2021 PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, reported that the Company will participate in H.C. Wainright 23rd Annual Global Investment Conference taking place virtually from September 13-15, 2021 (Press release, PharmAbcine, AUG 23, 2021, https://www.prnewswire.com/news-releases/pharmabcine-to-participate-in-hc-wainright-23rd-annual-global-investment-conference-301359591.html [SID1234586831]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the conference, Dr. Jin-San Yoo, CEO of PharmAbcine, will update PharmAbcine’s R&D progress via a presentation video, highlighting the Company’s core technology and pipelines such as olinvacimab, PMC-403, and PMC-309.

Olinvacimab, an anti-VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) fully human antibody, is the Company’s leading pipeline and is undergoing multiple global clinical trials. Currently, a Phase II olinvacimab mono study for bevacizumab-nonresponding rGBM (recurrent glioblastoma multiforme) patients is taking place at multiple sites in both US and Australia. Also, there are two Phase Ib olinvacimab and pembrolizumab combo trials in mTNBC and rGBM still ongoing in Australia.

PMC-403 is a novel TIE2-activating fully human antibody designed to stabilize and repair damaged blood vessels in a variety of diseases. PMC-403 is currently in development for treating AMD (Age-related Macular Degeneration), DME (Diabetic Macular Edema), and DR (Diabetic Retinopathy) which are common abnormal vascular-related eye diseases. The Company expects PMC-403 to enter global clinical trials for both ophthalmology and oncology in 2022.

PMC-309 is a novel anti-VISTA (V-domain Ig Suppressor of T cell Activation) antagonizing antibody in development for the treatment of various tumor types. VISTA plays a pivotal role in maintaining the immunosuppressive environment around the tumor cells and is expressed primarily on MDSC (Myeloid-Derived Suppressor Cells) and Tregs (regulatory T cells). Blocking VISTA pathways activates T cells’ immune responses and leads to better anti-tumor effects. PMC-309 is expected to enter a global clinical trial in 2022.

The Company will also join one-on-one meetings with institutional investors and private equity firms to seek investment opportunities.

The presentation video can be accessed at 7:00 AM (Eastern Standard Time) on Monday, September 13, 2021 and will be available for 90 days. For the webcasting link, request here.

About H.C. Wainwright & Co.

H.C. Wainwright is a full–service investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private companies across multiple sectors and regions. H.C. Wainwright & Co. also provides research and sales and trading services to institutional investors. According to Sagient Research Systems, H.C. Wainwright’s team is ranked as the #1 Placement Agent in terms of aggregate CMPO (confidentially marketed public offering), RD (registered direct offering) and PIPE (private investment in public equity) executed cumulatively since 1998.

On August 23, 2021 EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, and Manhattan BioSolutions, an emerging biotechnology company developing immunoregulatory therapies for the treatment of metastatic cancers, repored that they have been awarded a grant from the University at Buffalo Center for Advanced Technology in Big Data and Health Sciences (UB CAT) program (Press release, Manhattan BioSolutions, AUG 23, 2021, View Source [SID1234586954]). The UB CAT grant will enable the pharmacological assessment of novel computationally-designed biologic agents for the treatment of immune-mediated and viral diseases. This collaborative research will be conducted in partnership with the laboratory of Dr. Dhaval Shah, an Associate Professor at the Department of Pharmaceutical Sciences, University at Buffalo, whose cutting-edge research in protein therapeutics and pharmacokinetic-pharmacodynamic modeling has significantly impacted the drug development field around the globe.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The proposed project is based on the novel evolution-based, artificial intelligence (AI)-enabled antibody discovery platform developed by EVQLV. The in silico designed fully human antibody candidates against preselected targets will be tested experimentally for pharmacological effects in preclinical models to further demonstrate the utility of the EVQLV’s AI engine to deep-mine vast amounts of massive sequencing and structural databases to guide therapeutic antibody discovery and development.

Andrew Satz, Chief Executive Officer of EVQLV, commented: "Through our collaboration, we will continue to demonstrate how AI and machine learning can guide therapeutic antibody discovery and development. We strongly believe that generating and testing biologics, in the computer, prior to proceeding into biologic systems can accelerate how medicines reach patients in need".

Dr. Boris Shor, Chief Executive Officer, Manhattan BioSolutions, commented, "We are pleased to collaborate with EVQLV and Dr. Shah’s laboratory at the University at Buffalo. Our efforts will augment Manhattan BioSolutions’ current discovery plans aimed at the development of unique monoclonal antibodies targeting immunoregulatory receptors implicated in both cancer and inflammation".

Dr. Dhaval Shah commented: "The primary benefit of this collaboration is the strong synergy between our teams based on the unique expertise in computational science, translational pharmacology, and pharmacokinetic modeling of novel biologics. Together, we will be in a strong position to fully validate the computationally designed antibodies in preclinical experiments."